Written and maintained by CASRAI Editorial Board
Published
On this page
FinnGen is a public-private genomic research partnership and biomedical data platform based in Finland that combines genome-wide genotyping from more than 500,000 Finnish biobank participants with up to five decades of longitudinal digital healthcare register data. Launched in autumn 2017 and coordinated by the University of Helsinki through the Institute for Molecular Medicine Finland (FIMM), the initiative investigates the genetic determinants of human disease to accelerate therapeutic drug target discovery, improve diagnostic precision, and advance personalized medicine. By coupling comprehensive, unselected population-scale health registries with the unique genetic architecture of the Finnish population isolate, FinnGen provides researchers worldwide with exceptional statistical power to detect low-frequency and rare functional variants that influence disease risk and clinical trajectories.
What it is
FinnGen represents one of the largest and most systematically organized population-genomics initiatives in biomedical science. At its core, the project evaluates how genomic variation correlates with clinical outcomes across an entire national population. Rather than relying on disease-specific cohorts or volunteer convenience samples with high healthy-volunteer bias, FinnGen integrates blood and tissue samples collected across the entire Finnish public biobank network. Because Finland maintains universal, single-payer healthcare and comprehensive digital health records tied to unique personal identity codes assigned at birth, participants’ genomic profiles are mapped directly to lifelong medical encounters, surgical interventions, prescription drug purchases, and mortality data.
The scientific foundation of FinnGen relies heavily on the historical population genetics of Finland. The contemporary Finnish population was shaped by two major demographic bottlenecks: an initial founder migration approximately 4,000 years ago, followed by a secondary regional internal bottleneck during the 16th century when small numbers of families settled the central and northern areas of the country. This demographic history was followed by rapid population expansion without significant subsequent immigration until recent decades. In population genetics, this dynamic creates a pronounced founder effect. Hundreds of deleterious coding variants and loss-of-function (LoF) mutations that were randomly present in the founder families rose to substantial frequency through genetic drift, while many common European alleles were filtered out.
Consequently, low-frequency (minor allele frequency between 0.1% and 5%) and rare variants that are exceptionally difficult to study in large, pan-European or cosmopolitan populations are enriched by 2- to 100-fold in Finland. This enrichment gives investigators extraordinary statistical power to uncover novel genotype-phenotype correlations. A genetic variant associated with an altered risk of cardiovascular disease, inflammatory bowel disease, neurodegeneration, or metabolic dysfunction that might require millions of participants to detect in outbred populations can often achieve genome-wide significance within the 500,000 Finnish participants. Statistical findings generated by FinnGen feed directly into international repositories like the GWAS Catalog and target discovery pipelines such as the Open Targets Platform.
To balance open research dissemination with individual data privacy, FinnGen operates under a clear dual-tier data structure. Aggregate outputs—known colloquially as “Green Data”—consist of full genome-wide association study (GWAS) summary statistics, statistical fine-mapping credible sets, and gene-level burden tests. These data are released openly to the scientific community after a standard consortium exclusivity period and can be explored interactively or downloaded in bulk without requiring individual data access agreements. In contrast, “Red Data” consists of individual-level genotypes, whole-genome sequences, and linked longitudinal registry records. Red Data is governed by strict Finnish and European statutory privacy controls and is accessible only within certified secure virtual analysis environments under approved institutional research protocols.
Who runs it and what it covers
FinnGen is administered as an academic-industrial consortium governed by formal collaborative bodies designed to balance open public health research with pre-competitive pharmaceutical discovery. The project is led academically and administratively by the University of Helsinki, with operational coordination centralized at the Institute for Molecular Medicine Finland (FIMM), part of the Helsinki Institute of Life Science (HiLIFE). Scientific leadership is directed by Professor Aarno Palotie. The project is financed through a joint funding model: public research funding is provided by Business Finland (the Finnish government agency for innovation funding), matched by substantial pre-competitive investments from 13 leading global pharmaceutical companies: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), GlaxoSmithKline (GSK), Janssen (Johnson & Johnson), Maze Therapeutics, MSD (Merck & Co.), Novartis, Pfizer, and Sanofi.
Strategic and operational governance is supervised by a Steering Committee, which includes voting representation from the University of Helsinki, each participating public biobank, participating university hospital districts and wellbeing services counties, Business Finland, the Finnish Biobank Cooperative (FINBB), and industry partners. A dedicated Scientific Committee, supported by specialized clinical endpoint working groups, oversees cohort curation, analytical methodology, and scientific publication policies.
The sample collection for FinnGen is supplied by all public Finnish biobanks coordinated through the Finnish Biobank Cooperative (FINBB). Participating biobanks include Helsinki Biobank, Auria Biobank (Southwest Finland), Biobank of Eastern Finland, Central Finland Biobank, Northern Finland Biobank Borealis, Tampere Biobank, Finnish Red Cross Blood Service Biobank, and the Biobank of the Finnish Institute for Health and Welfare (THL). Over 500,000 biological samples have been recruited, representing roughly 10% of Finland's total population of 5.5 million citizens. The project has advanced across three planned phases:
- Phase 1 (2017–2020): Established national biobank sample intake, harmonized laboratory sample processing, deployed custom high-density genotyping microarrays, and demonstrated initial feasibility with 150,000 genotyped participants.
- Phase 2 (2020–2023): Scaled cohort genotyping to exceed the milestone of 500,000 participants, completed genome-wide association analyses across more than 2,400 disease endpoints, published landmark population genetic findings, and established broad public summary data releases.
- Phase 3 (2023–2027): Deepens phenotyping by transitioning from static binary diagnoses to longitudinal disease progression trajectories, integrating multi-omics layers (including plasma proteomics and metabolomics on selected subsets), expanding pharmacogenomic profiling, and validating functional mechanisms for prioritized therapeutic drug targets.
The phenotypic richness of FinnGen stems from its integration with Finland's statutory digital healthcare registries, which offer uninterrupted longitudinal health tracking dating back more than 50 years. Every resident in Finland is assigned a unique, lifelong Personal Identity Code (PIC / henkilötunnus), enabling deterministic, error-free record linkage across all public and private healthcare sectors. The core registries linked within FinnGen include:
- Care Register for Health Care (HILMO): Maintained by THL, documenting inpatient hospital discharges since 1969 and outpatient specialist hospital visits since 1998, categorized under historical ICD-8, ICD-9, and current ICD-10 diagnostic systems, alongside surgical procedure codes.
- Register of Primary Health Care (AvoHILMO): Capturing all outpatient visits to municipal primary healthcare clinics, health centers, and dental services since 2011, categorized using ICD-10 and ICPC-2 codes.
- Causes of Death Register: Maintained by Statistics Finland, recording immediate, underlying, and contributory causes of death for all deceased Finnish citizens since 1971.
- Finnish Cancer Registry: Mandatory nationwide reporting of all malignant and in-situ neoplastic diagnoses dating back to 1953.
- Social Insurance Institution (Kela) Drug Purchase and Reimbursement Registers: Comprehensive tracking of prescription drug dispenses categorized by Anatomical Therapeutic Chemical (ATC) classification codes since 1995, as well as formal medical approval records for special drug reimbursements for chronic conditions (e.g., hypertension, diabetes, asthma, rheumatoid arthritis) since 1964.
To translate millions of raw registry diagnosis codes into actionable research phenotypes, clinical expert panels within FinnGen curated thousands of standardized disease definitions termed “endpoints”. Each endpoint combines specific ICD codes, procedure codes, and prescription reimbursement criteria. Association tests are conducted across more than 2,700 disease endpoints using REGENIE, a high-performance machine learning and statistical framework designed for large biobanks. REGENIE accounts for sample relatedness via a leave-one-chromosome-out (LOCO) approach and incorporates Firth likelihood ratio corrections to handle severe case-control imbalance without inflating type I error rates. Genomic variants are imputed against the Sequencing Initiative Suomi (SISu) population-specific reference panel mapped to the GRCh38/hg38 human reference genome assembly. Statistical fine-mapping is subsequently performed using SuSiE and FINEMAP to identify 95% credible sets of causal variants.
The dataset table below outlines the evolution of sample sizes, analyzed clinical endpoints, and public release statuses across FinnGen data releases from R8 through R13.
How to search or use it
Researchers can interact with FinnGen data through interactive web portals or through formal raw data download channels. The following step-by-step walkthrough details how to query public association results using the official PheWeb and Risteys interfaces, inspect fine-mapped loci, and download summary datasets:
- Access the Public Analysis Portal: Open your web browser and navigate to the official FinnGen results portal (such as
r12.finngen.fiorresults.finngen.fi). Confirm that you are accessing the desired data release freeze (e.g., Release 12 for unrestricted public data). - Search by Phenotype Endpoint or Gene: In the central search bar on the PheWeb home page, enter your query. You can search by clinical disease name (e.g., “coronary artery disease”), standardized FinnGen endpoint code (e.g.,
I9_CHD), ICD-10 code (e.g.,I25), or human gene symbol (e.g.,PCSK9,TYK2,IL23R). As you type, the interface offers autocomplete suggestions showing matching endpoint descriptions and case counts. - Inspect the Interactive Manhattan and Q-Q Plots: Upon selecting an endpoint, PheWeb displays a full-genome Manhattan plot plotting genomic coordinates along the horizontal axis against association significance (-log10 p-value) on the vertical axis. The red horizontal line indicates the canonical genome-wide significance threshold (p < 5 × 10⁻⁸). Hover over individual data points to view variant identifiers (chromosomal position, reference and alternate alleles), nearest genes, and p-values. Review the accompanying Quantile-Quantile (Q-Q) plot to confirm that genomic inflation factors (λ) remain properly calibrated.
- Examine Regional LocusZoom Associations and Credible Sets: Click on a significant peak or enter a specific genomic window to open the regional association view. This view renders local linkage disequilibrium (LD) patterns relative to the lead index variant. For loci with significant signals, switch to the Fine-Mapping tab to inspect Bayesian credible sets generated by SuSiE and FINEMAP. Check the Posterior Inclusion Probability (PIP) values for each variant; variants with high PIPs (>0.5 or >0.8) represent primary candidates for causal biological disruption.
- Evaluate Variant Details and Population Frequency: Click any individual variant identifier (formatted as
chr:pos:ref:alt, such as19:11100000:G:A) to open the dedicated Variant Browser. Review the estimated effect size (beta for continuous traits or log-odds ratio for binary endpoints), standard error, and effect allele frequency. Compare the minor allele frequency (MAF) observed in the FinnGen cohort with that recorded in the Genome Aggregation Database (gnomAD) for Non-Finnish Europeans (NFE) to determine whether the variant is substantially enriched in Finland due to the founder effect. - Analyze Clinical Trajectories and Comorbidities in Risteys: Open the companion Risteys platform (
risteys.finngen.fi) and input the same endpoint code. Risteys provides detailed epidemiological breakdowns, including cumulative incidence curves stratified by sex and age of onset, hazard ratios for antecedent and subsequent diagnoses, and clinical comorbidity trajectory networks that illustrate the chronological progression of related conditions before and after initial diagnosis. - Download Bulk Summary Statistics (Green Data): To perform local secondary analyses—such as polygenic risk score (PRS) construction, Mendelian randomization, or cross-trait genetic correlation—navigate to the FinnGen documentation portal at
finngen.gitbook.io/documentation/data-download. Complete the brief online data download request form. Once submitted, you will receive manifest files (e.g.,finngen_R13_manifest.tsv) containing Google Cloud Storage bucket URLs where gzipped summary statistic files, fine-mapping tables, and variant annotation files can be retrieved viacurl,wget, or Google Cloud CLI. - Request Individual-Level Microdata (Red Data): If your research hypothesis requires individual-level genotype data, longitudinal electronic health records, or biological samples, submit a formal project application through the Fingenious portal operated by FINBB (
fingenious.fi). Following biobank feasibility assessment, submit a centralized data permit application to Findata (findata.fi) under the Finnish Act on Secondary Use of Health and Social Data (552/2019). Approved projects are provisioned within certified secure remote processing environments (e.g., Findata's Kapseli or CSC's secure cloud infrastructure) where individual-level data can be analyzed without raw microdata leaving the protected perimeter.
Practical Scenarios by Research Audience
- Academic Statistical Geneticists: Can freely download Green Data summary statistics to run cross-trait LD score regression (LDSC), build multi-ancestry polygenic risk scores, or fine-map causal variants alongside datasets from the UK Biobank and BioBank Japan.
- Translational Drug Discovery Teams: Can leverage PheWeb and the Coding Variant Browser to evaluate target safety and efficacy. Identifying human “knockout” variants (homozygous loss-of-function carriers) in Finnish biobanks reveals whether pharmacological inhibition of a specific target mimics protective phenotypes or triggers adverse clinical endpoints.
- Institutional Research Offices and Compliance Officers: Must recognize that accessing individual-level FinnGen data requires formal institutional data use agreements, documented ethical review, Findata secondary use permits, and compliance with the European Union General Data Protection Regulation (GDPR) within certified enclave computing environments.
Strengths and limits
Understanding the methodological capabilities and boundaries of FinnGen is vital for designing robust genetic epidemiology and therapeutic validation studies.
Strengths
- Exceptional Power for Rare and Low-Frequency Functional Alleles: Due to Finland's historical population bottlenecks and subsequent isolation, deleterious protein-altering variants that remain exceptionally rare in broader European cohorts are concentrated at frequencies that allow robust statistical association testing in a cohort of 500,000 individuals.
- Unrivaled Depth of Longitudinal Health Registries: Unlike biobanks that rely primarily on self-reported questionnaires or incomplete regional hospital EHRs, FinnGen captures complete, cradle-to-grave healthcare encounters spanning inpatient, outpatient specialist, primary care, cancer, medication reimbursement, and cause-of-death registries across up to 50 years.
- Standardized, Clinician-Curated Phenotype Endpoints: Rather than relying on raw billing codes that frequently introduce misclassification, FinnGen's clinical expert working groups systematically developed and validated rule-based endpoints that harmonize historical ICD-8, ICD-9, and ICD-10 codes with surgical procedures and medication dispenses.
- Public Availability of Green Data: Full summary statistics and fine-mapping credible sets are released openly to the scientific community following a 12-month partner embargo, complying with FAIR data principles and enabling global secondary utilization without financial barriers.
- Multi-Omics Expansion in Phase 3: Ongoing integration of high-throughput plasma proteomics and metabolomics offers unprecedented opportunities to dissect intermediate biological pathways bridging genetic variation and clinical disease manifestations.
Limits
- Limited Portability of Population-Specific Findings: Many of the most impactful loss-of-function variants discovered through FinnGen are private to or heavily enriched in the Finnish population. While the biological mechanisms and drug target insights are globally relevant, individual variant associations and polygenic score weights often have limited direct transferability to African, Asian, Hispanic/Latino, or admixed populations without trans-ethnic fine-mapping.
- Array Genotyping and Imputation Constraints: Core FinnGen cohorts are genotyped using custom Affymetrix microarrays followed by statistical imputation against the SISu reference panel. While imputation quality is exceptionally high for Finnish alleles down to 0.1% MAF, ultra-rare private non-coding variants, complex structural rearrangements, and short tandem repeats cannot be resolved without high-coverage whole-genome sequencing (WGS).
- Consortium Exclusivity Embargo: Industry partners and academic consortium members benefit from a 12-month exclusivity window on each newly frozen data release before full summary statistics become available to the public, creating a temporary information gap for external investigators.
- Strict Enclave Compute Requirements for Individual Microdata: In compliance with the Finnish Act on Secondary Use of Health and Social Data (552/2019) and European GDPR standards, individual-level genotypes and registry records cannot be downloaded or transferred to external institutional servers. Researchers must execute all analyses inside certified, audited remote desktop environments (such as Kapseli or CSC).
Alternatives
While FinnGen provides unique statistical leverage for exploring disease endpoints linked to founder-enriched coding variants, researchers frequently evaluate or cross-validate findings against other major international population-scale biobanks. The table below compares the foundational characteristics, population structures, and access frameworks of FinnGen alongside four leading global cohorts.
| Platform / Biobank | Primary Population Architecture | Cohort Sample Size | Health Registry Linkage Scope | Primary Genomic Data Modality | Access & Governance Model |
|---|---|---|---|---|---|
| FinnGen | Genetically isolated founder population (Finland) | 500,000+ | Nationwide longitudinal digital registers (50+ years: HILMO, AvoHILMO, Kela, Cancer, Death) | Custom Affymetrix array + SISu population imputation (GRCh38); targeted multi-omics | Public-private partnership; open summary stats (Green); individual data via Findata/Fingenious in secure enclaves (Red) |
| UK Biobank | Predominantly White British; urban/regional volunteers (aged 40–69 at baseline) | ~502,000 | NHS electronic health records, Hospital Episode Statistics (HES), cancer and death registries | Affymetrix array, exome sequencing (WES), and whole-genome sequencing (WGS) across all 500k | Public charitable trust; open application process for bona fide researchers; data access fee; downloadable microdata or cloud analysis (Research Analysis Platform) |
| All of Us Research Program | Highly diverse, historically underrepresented US populations (multi-ethnic) | 1,000,000 target (>750,000 enrolled; >400,000 with genomic data) | Electronic health records from participating healthcare provider organizations, participant surveys, digital health sensors | Illumina whole-genome sequencing (WGS) and global diversity genotyping arrays | US National Institutes of Health (NIH); tier-based access (Public, Registered, Controlled); cloud workbench enclave (Researcher Workbench) |
| BioBank Japan (BBJ) | Hospital-based disease cohort (Japanese ancestry) | ~267,000 patients across 51 common diseases | Hospital medical records, clinical questionnaires, follow-up survival surveys | SNP arrays imputed against Japanese reference panels; whole-genome sequencing in disease subsets | Academic consortium (University of Tokyo / RIKEN / AMED); formal data sharing application via NBDC / JGA |
| deCODE genetics | Isolated founder population (Iceland) | ~160,000+ (over half the adult Icelandic population) | Icelandic national healthcare system records, detailed family genealogies spanning centuries | Whole-genome sequencing, chip genotyping, deep multi-omics, extensive genealogical imputation | Commercial subsidiary (Amgen); proprietary database; academic collaborations governed through specific scientific agreements |
When choosing between these resources, investigators must weigh genetic architecture against diversity requirements. For drug target validation, FinnGen and deCODE genetics offer unmatched efficiency in identifying protective or deleterious loss-of-function variants due to founder enrichment. However, for developing polygenic risk scores intended for equitable clinical deployment across diverse global healthcare systems, multi-ethnic resources like the All of Us Research Program or trans-ancestry meta-analyses combining FinnGen, UK Biobank, and BioBank Japan are strictly required.
FAQ
What is the difference between FinnGen Green Data and Red Data?
Green Data consists of fully de-identified, aggregated statistical outputs—including genome-wide association study (GWAS) summary statistics, fine-mapping credible sets from SuSiE and FINEMAP, and gene-level burden test results. Green Data is released publicly after an exclusivity period and can be freely browsed or downloaded. Red Data consists of sensitive individual-level microdata, including participant genotypes, whole-genome sequences, and linked longitudinal registry records. Red Data is legally protected under Finnish and EU data privacy regulations and can only be accessed within certified secure computing enclaves (such as Kapseli) following formal approval from Findata and participating biobanks.
How can international researchers access FinnGen individual-level data?
International researchers can access individual-level data (Red Data) by submitting a formal scientific research plan through the Fingenious portal (fingenious.fi) operated by the Finnish Biobank Cooperative (FINBB). Once biobank sample and data feasibility is established, researchers apply for a secondary use data permit from Findata (findata.fi) under the Finnish Act on Secondary Use of Health and Social Data (552/2019). If approved, analyses must be conducted within a certified secure remote desktop environment (e.g., Kapseli); individual-level raw data cannot be transferred out of the secure perimeter.
What is the Finnish founder effect and why does it matter for GWAS?
The Finnish founder effect refers to historical population bottlenecks that occurred thousands and hundreds of years ago as small groups of founders established communities across Finland. In the subsequent rapid population expansion without significant external admixture, certain rare genetic variants present in founders expanded dramatically through genetic drift, becoming 2- to 100-fold more common than in outbred European populations. In genome-wide association studies, this enrichment provides substantial statistical power to discover phenotypic associations for rare, protein-altering mutations that would require millions of participants to detect elsewhere.
What statistical software does FinnGen use for association tests and fine-mapping?
FinnGen performs genome-wide association tests using REGENIE, an efficient C++ framework that implements a leave-one-chromosome-out (LOCO) approach to adjust for polygenic background and cryptic relatedness. REGENIE applies Firth likelihood ratio tests to correct for extreme case-control imbalance common in rare disease phenotypes. For loci reaching genome-wide significance, Bayesian statistical fine-mapping is performed using SuSiE (Sum of Single Effects) and FINEMAP to calculate posterior inclusion probabilities (PIPs) and delineate 95% credible sets of causal variants.
How do you cite FinnGen in an academic publication?
When publishing research that utilizes FinnGen data, authors are requested to cite the primary project paper: Kurki, M. I., Karjalainen, J., Palta, P., et al. “FinnGen provides genetic insights from a well-phenotyped isolated population.” Nature 613, 508–518 (2023), doi:10.1038/s41586-022-05473-8. Additionally, manuscripts must include the standardized acknowledgement: “We want to acknowledge the participants and investigators of the FinnGen study.” When referencing specific analytical pipelines or releases, authors should also cite the specific FinnGen GitBook documentation URL and release freeze (e.g., Release 12).
Are FinnGen summary statistics free to download and use?
Yes. All public releases of FinnGen summary statistics (Green Data)—including per-variant effect sizes, p-values, and fine-mapping credible sets across thousands of clinical endpoints—are freely available for non-commercial and academic secondary use. Researchers must complete a standard online data request form at finngen.gitbook.io/documentation/data-download to access the manifest files and Google Cloud Storage buckets hosting the data.
How does FinnGen define and validate clinical disease endpoints?
Clinical endpoints are constructed by specialized clinical expert groups comprised of physicians, geneticists, and epidemiologists. Rather than relying solely on single billing codes, each endpoint integrates rule-based logic combining historical ICD-8 (1969–1986), ICD-9 (1987–1995), and ICD-10 (1996–present) diagnostic codes, NOMESCO surgical procedure classifications, and Kela prescription reimbursement entitlements. Endpoints are periodically refined to ensure consistency across decades of evolving diagnostic practices.
Can FinnGen results be integrated into Open Targets or the GWAS Catalog?
Yes. Following the expiration of the consortium exclusivity period, FinnGen public summary statistics and fine-mapped association credible sets are routinely harmonized and integrated into leading international biological knowledgebases, including the GWAS Catalog and the Open Targets Platform, where they contribute to systematic target prioritization and evidence scoring across thousands of complex diseases.
Sources
The information in this guide was compiled from official platform documentation, statutory authorities, and primary peer-reviewed literature:
- FinnGen Official Project Portal:
https://www.finngen.fi/en(Accessed 2026-11-14). - FinnGen Public Documentation & Data Releases (GitBook):
https://finngen.gitbook.io/documentation/(Accessed 2026-11-14). - FinnGen Data Download Guidelines & Manifests:
https://finngen.gitbook.io/documentation/data-download(Accessed 2026-11-14). - Kurki, M. I., Karjalainen, J., Palta, P., et al. “FinnGen provides genetic insights from a well-phenotyped isolated population.” Nature 613, 508–518 (2023). DOI: 10.1038/s41586-022-05473-8.
- Findata (Social and Health Data Permit Authority):
https://www.findata.fi/en/(Accessed 2026-11-14). - Fingenious (FINBB – Finnish Biobank Cooperative):
https://fingenious.fi/(Accessed 2026-11-14).
Data: FinnGen Data Releases, Analyzed Cohort Sizes, and Curated Clinical Endpoints (R8-R13)
Comparative specifications of FinnGen data freezes from Release 8 through Release 13, detailing analyzed biobank cohort sizes, curated clinical disease endpoints, consortium release timelines, public availability status, and reference genome assembly. Compiled directly from official FinnGen public documentation.
Period covered: 2021/2026. Coverage: Finland.
| Release | Analyzed Cohort Size (samples) | Curated Clinical Endpoints (endpoints) | Consortium Partner Release Year | Public Release Status | Reference Genome Assembly |
|---|---|---|---|---|---|
| Release 8 | 342499 | 2202 | 2021 | Public | GRCh38 |
| Release 9 | 375000 | 2263 | 2022 | Public | GRCh38 |
| Release 10 | 412181 | 2408 | 2022 | Public | GRCh38 |
| Release 11 | 453733 | 2447 | 2023 | Public | GRCh38 |
| Release 12 | 500348 | 3000 | 2023 | Public | GRCh38 |
| Release 13 | 500186 | 2755 | 2025 | Partner Embargo | GRCh38 |
Sources
- FinnGen Public Documentation: Data Releases (accessed 2026-11-14)
- FinnGen Public Documentation: Release 13 Summary (accessed 2026-11-14)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







